News about Global Pharma

US FDA Approves Olumiant for Pediatric Alopecia Areata

US FDA has approved Lilly’s Olumiant (baricitinib) for severe alopecia areata in patients aged 12 and older, based on the phase 3 BRAVE-AA-PEDS study.

Global Pharma | 28/09/2026 | By News Bureau

US FDA Approves Belzutifan-Lenvatinib for Advanced RCC

The US FDA has approved belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component.

Global Pharma | 28/09/2026 | By News Bureau

Merck's Remigromig Targets Wnt Pathway in Eye Disease

Merck’s remigromig meets the primary endpoint in the phase 2b/3 BRUNELLO study in adults with Diabetic Macular Edema (DME).

Global Pharma | 25/09/2026 | By News Bureau

Xenon Submits NDA for Azetukalner in Focal Seizures to US FDA

Xenon Pharmaceuticals has submitted an NDA to the US FDA for azetukalner in focal seizures, supported by data from the Phase 2b X-TOLE and Phase 3 X-TOLE2 trials.

Global Pharma | 21/09/2026 | By News Bureau

Nuvation Bio Gets US FDA sNDA Approval for IBTROZI

Nuvation Bio has announced US FDA approval of sNDA for IBTROZI (taletrectinib), updating duration of response in TKI-naïve ROS1-positive NSCLC.

Global Pharma | 19/09/2026 | By News Bureau

Gilead Accelerates Access to Once-Yearly HIV Drug

Gilead speeds global access for once-yearly HIV drug lenacapavir, signing 6 royalty-free licensing deals for supplying in 120 high-incidence countries.

Global Pharma | 18/09/2026 | By News Bureau

Viatris Gets Approval for WAKIX in Japan

Viatris has got approval for WAKIX (Pitolisant), a first-in-class treatment for narcolepsy and Excessive Daytime Sleepiness (ESD) from sleep apnea, in Japan.

Global Pharma | 18/09/2026 | By News Bureau

Japan Approves Leqembi Pen, a Subcutaneous Formulation

Japan has approved Leqembi Pen, a once-weekly subcutaneous (SC) formulation for early Alzheimer's, offering at-home dosing alongside the intravenous (IV) option.

Global Pharma | 17/09/2026 | By News Bureau

US FDA Approves Telix's Brain Cancer Imaging Drug Pixclara

The US Food and Drug Administration (FDA) has approved Telix’s Pixclara, the first FET-PET imaging drug for glioma, helping differentiate recurrent or progressive brain cancer from treatment-related changes.

Global Pharma | 15/09/2026 | By News Bureau |  181

Sun Pharma Subsidiaries Reach Settlement in US Generic Drug Pricing Antitrust Litigation

Sun Pharma subsidiaries have reached a settlement with a plaintiff in a US generic drug pricing antitrust case for a confidential amount.

Global Pharma | 15/09/2026 | By News Bureau